OverviewSuggest Edit

Progenics Pharmaceuticals develops medicines and other technologies to target and treat cancer in the United States and internationally. The Company’s primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant and/or recurrent pheochromocytoma and paraganglioma.
TypePublic
Founded1986
HQNew York, US
Websiteprogenics.com
Employee Ratings2.5

Latest Updates

Employees (est.) (Dec 2019)105(+33%)
Revenue (FY, 2019)$35 M(+124%)
Share Price (Jun 2020)$4.1
Cybersecurity ratingBMore

Key People/Management at Progenics Pharmaceuticals

David W. Mims

David W. Mims

Interim CEO, CFO & Director
Gérard Ber

Gérard Ber

Director
Asha Das

Asha Das

Chief Medical Officer
Bradley L. Campbell

Bradley L. Campbell

Director
Vivien Wong

Vivien Wong

Executive Vice President, Development
Eric J. Ende

Eric J. Ende

Director
Show more

Progenics Pharmaceuticals Office Locations

Progenics Pharmaceuticals has an office in New York
New York, US (HQ)
285 Fulton St
Show all (1)

Progenics Pharmaceuticals Financials and Metrics

Progenics Pharmaceuticals Revenue

Progenics Pharmaceuticals's revenue was reported to be $34.99 m in FY, 2019
USD

Revenue (Q1, 2020)

6.2m

Gross profit (Q1, 2020)

4.7m

Gross profit margin (Q1, 2020), %

75.1%

Net income (Q1, 2020)

(16.8m)

EBIT (Q1, 2020)

(15.9m)

Market capitalization (26-Jun-2020)

355.0m

Closing stock price (26-Jun-2020)

4.1

Cash (31-Mar-2020)

29.5m

EV

378.4m
Progenics Pharmaceuticals's current market capitalization is $355 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

84.8m14.0m7.9m44.4m8.7m69.4m11.7m15.6m35.0m

Cost of goods sold

3.2m

Gross profit

31.8m

Gross profit Margin, %

91%
Quarterly
USDQ2, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

74.4m2.2m1.8m1.1m2.2m1.8m867.0k1.8m1.5m41.7m248.0k1.9m1.4m2.5m8.5m53.9m2.3m2.7m3.2m3.9m5.3m4.3m10.0m5.6m6.2m

Cost of goods sold

493.0k1.3m1.6m

Gross profit

9.5m4.3m4.7m

Gross profit Margin, %

95%77%75%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

70.1m58.8m65.9m119.3m74.1m138.9m90.6m137.7m42.0m

Accounts Receivable

1.5m6.9m2.9m109.0k3.5m4.9m4.0m3.8m16.0m

Prepaid Expenses

1.7m1.9m2.5m5.6m2.3m2.6m

Inventories

Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

10.4m(35.4m)(42.6m)4.4m(39.1m)10.7m(51.0m)(67.7m)(68.6m)

Depreciation and Amortization

2.1m1.3m939.0k545.0k565.0k2.1m1.1m1.5m2.4m

Inventories

(2.9m)

Accounts Payable

(3.4m)(691.0k)(2.0m)58.0k2.2m243.0k2.8m(2.9m)808.0k
USDQ2, 2011

Financial Leverage

1.1 x
Show all financial metrics

Progenics Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

SecurityScorecard logo

Progenics Pharmaceuticals Online and Social Media Presence

Embed Graph

Progenics Pharmaceuticals News and Updates

Progenics Pharmaceuticals stock soars 29% on news of positive results in prostate cancer drug trial

Progenics Pharmaceuticals, Inc. said Monday a late-stage trial of a treatment for prostate cancer met its main goal. The New York-based company said the phase 3 trial called Condor evaluating the diagnostic performance of PyL(TM) ((18) F-DCFPyL) in men with biochemical recurrence of prostate cancer…

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation Regarding the November 12, 2019 Registration Statement of Progenics Pharmaceuticals, Inc.

NEW YORK, Dec. 11, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating the Registration Statement filed on November 12, 2019 by the buyer,...

Progenics Pharmaceuticals Announces Presentations at the Radiological Society of North America (RSNA) Annual Meeting

NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that four abstracts highlighting PyL (¹⁸F-DCFPyL) have been selected…

SHAREHOLDER ALERT: WeissLaw LLP Investigates Progenics Pharmaceuticals, Inc.

NEW YORK, Oct. 4, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company") (NASDAQ: PGNX) in connection with the proposed acquisition of the Company by...

Progenics Pharmaceuticals Strengthens Management Team with Appointment of Huw Jones as Vice President, Commercial

-Commercial Leader Brings Deep Experience in Radiopharmaceuticals and Oncology- -Commercial Leader Brings Deep Experience in Radiopharmaceuticals and Oncology-

Velan Releases Detailed Presentation on Progenics Pharmaceuticals

ALPHARETTA, Ga., June 20, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(NASDAQ:PGNX), comprised of successful specialty ...
Show more

Progenics Pharmaceuticals Blogs

Progenics Pharmaceuticals Announces Presentation at the 2020 SNMMI Mid-Winter Meeting

NEW YORK, Jan. 16, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that an abstract highlighting data from its PSMA AI program has been

Progenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyL™ in Prostate Cancer Achieved Primary Endpoint

Progenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyL™ in Prostate Cancer Achieved Primary Endpoint Content Import Mon, 12/23/2019 - 07:00 Progenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyL™ in Prostate Cancer Achieved Primary Endpoint Dec 23, 2019 …

Progenics Pharmaceuticals Appoints David Mims as Interim Chief Executive Officer

NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced its Board of Directors has appointed David W.

Progenics Pharmaceuticals Announces Delivery of Consents and Revocations to Independent Inspector of Elections

Progenics Pharmaceuticals Announces Delivery of Consents and Revocations to Independent Inspector of Elections Content Import Fri, 11/08/2019 - 16:05 Progenics Pharmaceuticals Announces Delivery of Consents and Revocations to Independent Inspector of Elections Nov 08, 2019 …

Progenics Pharmaceuticals Announces Business Update And Third Quarter 2019 Financial Results

Progenics Pharmaceuticals Announces Business Update And Third Quarter 2019 Financial Results Content Import Thu, 11/07/2019 - 08:01 Progenics Pharmaceuticals Announces Business Update And Third Quarter 2019 Financial Results Nov 07, 2019 This release is a back…

Progenics Reminds Shareholders that November 17 is the True Deadline for Velan’s Consent Solicitation

Warns Shareholders to Ignore Earlier and Illusory Consent Cutoff Set by Velan Urges Shareholders to Review the S-4 Filing that Will be Made the Week of November 11 about the Value Maximizing Lantheus Transaction in Order to Make a Fully Informed Final Decision about the Consent Solicitation and
Show more

Progenics Pharmaceuticals Frequently Asked Questions

  • When was Progenics Pharmaceuticals founded?

    Progenics Pharmaceuticals was founded in 1986.

  • Who are Progenics Pharmaceuticals key executives?

    Progenics Pharmaceuticals's key executives are David W. Mims, Gérard Ber and Asha Das.

  • How many employees does Progenics Pharmaceuticals have?

    Progenics Pharmaceuticals has 105 employees.

  • What is Progenics Pharmaceuticals revenue?

    Latest Progenics Pharmaceuticals annual revenue is $35 m.

  • What is Progenics Pharmaceuticals revenue per employee?

    Latest Progenics Pharmaceuticals revenue per employee is $333.2 k.

  • Who are Progenics Pharmaceuticals competitors?

    Competitors of Progenics Pharmaceuticals include Northwest Biotherapeutics, Merrimack Pharmaceuticals and CytomX Therapeutics.

  • Where is Progenics Pharmaceuticals headquarters?

    Progenics Pharmaceuticals headquarters is located at 285 Fulton St, New York.

  • Where are Progenics Pharmaceuticals offices?

    Progenics Pharmaceuticals has an office in New York.

  • How many offices does Progenics Pharmaceuticals have?

    Progenics Pharmaceuticals has 1 office.